ACR–ACNM–ARS–SNMMI–SPR PRACTICE PARAMETER FOR TREATMENT OF BENIGN AND MALIGNANT THYROID DISEASE WITH I-131 SODIUM IODIDE
PREAMBLE
I. INTRODUCTION
II. DEFINITION
III. INDICATIONS
IV. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
A. General Procedures
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
B. Unique Situations
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
C. Treatment of Benign Thyroid Disease
1. Therapy for Hyperthyroidism
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
D. Treatment of Malignant Thyroid Disease
1. Clinical Evaluation
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
D. Treatment of Malignant Thyroid Disease
2.
Radiation precautions, and considerations unique to therapy of malignant thyroid disease
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
D. Treatment of Malignant Thyroid Disease
3. Therapy
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
D. Treatment of Malignant Thyroid Disease
4. Complications
VI. DOCUMENTATION
VII. ACR STATEMENT On THERAPEUTIC USE OF UNSEALED RADIOPHARMACEUTICAL SOURCES
VIII. RADIATION SAFETY
IX. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION
ACKNOWLEDGEMENTS
Writing Committee – members represent their societies in the initial and final revision of this practice parameter
|
|
|
|
|
Committee on Practice Parameters – Nuclear Medicine and Molecular Imaging
(ACR Committee responsible for sponsoring the draft through the process)
Committee on Practice Parameters and Technical Standards
(ACR Committee responsible for sponsoring the draft through the process)
Committee on Practice Parameters – Pediatric Imaging
(ACR Committee responsible for sponsoring the draft through the process)
Committee on Practice Parameters – Radiation Oncology
(ACR Committee responsible for sponsoring the draft through the process)
Comments Reconciliation Committee
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REFERENCES